MoonLake Immunotherapeutics

MoonLake Immunotherapeutics reached the public markets through a 2022 business combination with Helix Acquisition Corp (Nasdaq: HLXA), a healthcare-focused blank-check company that completed its initial public offering in 2021 under the sponsorship of Helix Acquisition Holdings LLC. The de-SPAC transaction produced a clinical-stage biopharmaceutical company concentrated on inflammatory and immunological diseases, anchored by sonelokimab, an investigational IL-17A/F nanobody being evaluated in conditions including hidradenitis suppurativa and psoriatic arthritis. MoonLake filed an 8-K with the SEC on August 10, 2026, as a fully public operating company. Sign up on SpacDesk for complete filing histories, deal timelines, and SPAC analytics covering MoonLake and the broader market.